Global Point-of-Care Connectivity Solutions Market to Reach $1.7 Billion by 2032 | Abbott, Roche, Siemens Healthineers and GE HealthCare Accelerate AI-Driven Care
The global point-of-care connectivity solutions market is projected to grow from $1.1 billion in 2025 to $1.7 billion by 2032, driven by healthcare digitization and demand for real-time patient data. Key players like Abbott, Roche, Siemens Healthineers, and GE HealthCare are leveraging AI and other advanced technologies to enhance these solutions. The market is segmented by offering, application, end-use, and geography, with significant growth expected in the software segment and the China market.
BSX: Boston Scientific sets senior notes offering to fund Penumbra deal
Boston Scientific (BSX) is issuing four series of senior notes to finance the cash portion of its acquisition of Penumbra. If the Penumbra deal does not close by the January 2027 deadline, Boston Scientific will be required to redeem the notes at 101% of principal plus accrued interest, although the offering itself is not conditional on the deal's completion. The proceeds are not held in escrow, and the company plans to use them along with other financing for the acquisition and general corporate purposes.
BSX: Boston Scientific sets senior notes offering to fund Penumbra deal
Boston Scientific (BSX) is offering four series of senior notes to finance the cash portion of its acquisition of Penumbra. If the Penumbra deal does not close by the specified deadline, the company is obligated to redeem the notes at 101% of the principal plus accrued interest, although the offering itself is not conditional on the deal's completion. The proceeds from the offering will not be held in escrow, and no security interest is granted to the noteholders.
If the Penumbra deal misses its deadline, Boston Scientific (BSX) must repay all four series of notes.
Boston Scientific Corporation is offering four series of senior notes to finance its proposed acquisition of Penumbra, valued at approximately $14.5 billion. The acquisition, approved by Penumbra stockholders in May 2026, is expected to close in early 2027. A Special Mandatory Redemption clause dictates that if the acquisition is not completed by January 14, 2027 (with potential extensions to January 14, 2028), Boston Scientific must redeem all notes at 101% of the principal plus accrued interest.
Form 424B5 BOSTON SCIENTIFIC CORP
Boston Scientific Corporation is offering several series of senior unsecured notes to finance the cash consideration for its proposed acquisition of Penumbra, Inc. The offering is not conditioned on the acquisition's completion, but if the acquisition does not occur by the specified date, Boston Scientific will be required to redeem the notes at 101% of their principal amount plus accrued interest. The notes will be structurally junior to the debt of its subsidiaries and may be subject to optional redemption by the company.
If the Penumbra deal misses its deadline, fixed-rate notes backed by Boston Scientific (BSX) must be redeemed.
Boston Scientific's finance subsidiary, AMS Europe, is offering euro-denominated notes to fund the proposed $14.5 billion acquisition of Penumbra. If the acquisition is not completed by January 14, 2027 (with a potential extension to January 14, 2028), or if Boston Scientific decides not to proceed, the fixed-rate notes will be subject to a special mandatory redemption at 101% of their principal amount plus accrued interest. The offering is not contingent on the acquisition closing, and the notes are senior unsecured obligations guaranteed by Boston Scientific.
Sintx Technologies, Inc. (SINT) stock price, news, quote and history
Sintx Technologies, Inc. (SINT) stock closed at $1.2050, down 2.82%, with a market cap of $9.108 million. The company, which specializes in silicon nitride biomaterials for medical and other applications, has seen significant negative returns over the past year, with a 1-year return of -63.48% and a 5-year return of -99.99%. Analysts maintain a "Buy" rating with a target price of $12.50.
Jack-in-the-Stox: Holmium, The Critical Rare Earth in the Operating Room
This article highlights holmium, a heavy rare earth element crucial for surgical lasers used in treating benign prostatic hyperplasia (BPH), as an example of overlooked critical mineral applications. Despite American and European manufacturing capabilities for holmium laser systems and crystals, the United States remains 100% import-dependent on China for holmium compounds and metals. The author emphasizes that securing critical mineral supply chains requires understanding specific industrial requirements and procurement relationships, not just mining statistics.
Windward Bio to present at Jefferies London Global Healthcare Conference on Nov 18, 2026
Windward Bio Group AG, a clinical-stage biotech company, announced its presentation at the Jefferies London Global Healthcare Conference on November 18, 2026. The company will discuss its lead product, WIN378, for severe asthma and COPD, and early trials for WIN027, offering investors insights into its pipeline developments. The article also provides a snapshot of healthcare sector activity on Pluang, noting movements in US health stocks.
Boston Scientific appoints new lead independent director and updates executive compensation plans
Boston Scientific Corporation has announced that David S. Wichmann will become the new Lead Independent Director, effective January 1, 2027, succeeding Edward J. Ludwig. The company's board also approved the 2027 Annual Bonus Plan and two long-term incentive programs (rTSR PSP and Organic Net Sales PSP) for executive compensation, linking payouts to company performance metrics. These updates follow recent analyst downgrades due to concerns over future growth projections and the impact of a cyberattack on Q3 2026 revenue and 2027 guidance.
Form 8K Boston Scientific Corp For: 17 November By Investing.com
Boston Scientific Corp. filed a Form 8K on November 17, 2026. This filing, a standard disclosure for significant events, was reported by Investing.com. The article also notes a 1.51% drop in Boston Scientific's stock (BSX) during this period.
Form 424B2 BANK OF NOVA SCOTIA
The Bank of Nova Scotia has filed a Form 424B2 for Autocallable Contingent Coupon Barrier Notes due November 24, 2028, linked to the common stock of Boston Scientific Corporation. These unsubordinated and unsecured debt securities offer contingent coupons if certain conditions are met, and an automatic call feature. Investors face risks including potential loss of principal, no guaranteed interest, and credit risk of the Bank.
David S. Wichmann to become lead independent director at Boston Scientific (BSX) on January 1, 2027.
Boston Scientific Corporation (BSX) has approved its 2027 annual cash bonus plan, with a maximum individual payout of 225% of target, and two executive performance-share programs for 2027-2029. These programs link awards to relative total shareholder return against the S&P 500 Healthcare Index and organic net sales growth against the company's financial plan. Additionally, independent director David S. Wichmann will assume the role of Lead Independent Director effective January 1, 2027, succeeding Edward J. Ludwig.
Electroceutical Devices Market Size, Share & Forecast 2036
The electroceutical devices market is projected to grow from USD 25.1 billion in 2026 to USD 49.2 billion by 2036, at a CAGR of 7.0%. This growth is driven by increasing adoption of advanced neuromodulation, expansion of closed-loop and personalized neuromodulation, and strategic portfolio consolidation among key players. Implantable devices, cardiovascular applications, and hospitals are expected to maintain their leading positions in the market segments.
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
Senseonics and Beta Bionics have commercially launched the integration of Eversense 365, a year-long implantable continuous glucose monitor, with the iLet Bionic Pancreas for automated insulin delivery. This system autonomously determines insulin doses without requiring carbohydrate counting, aiming to simplify diabetes management. The companies also plan future integration with Beta Bionics' Mint tubeless patch pump to broaden insulin delivery options.
Medtronic plans US$380M Contego Medical acquisition for vascular portfolio
Medtronic plc announced plans to acquire privately held Contego Medical, Inc. for US$380 million, expanding its carotid-artery and clot-removal portfolio. The deal, which includes potential later payments and is expected to close in Medtronic's fiscal third quarter, is projected to cause a small reduction in Medtronic's adjusted earnings per share in fiscal 2027 and 2028 before becoming neutral or positive after fiscal 2028. This acquisition builds on an existing distribution agreement and integrates Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices into Medtronic's offerings.
Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology
Kestra Medical Technologies announced the publication of primary results from its ACE-PAS study in the Journal of Cardiovascular Electrophysiology. This study, the largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, enrolled over 21,000 patients and demonstrated 100% all-shock conversion success and sustained daily wear of the ASSURE system. The findings reinforce the system's clinical value across WCD indications and highlight its importance in protecting patients from arrhythmic risk during recovery periods.
PMGC Holdings Inc. [NASDAQ: ELAB] Reports Record Q3 Revenue, Up...
PMGC Holdings Inc. (NASDAQ: ELAB) reported record Q3 2026 revenue of $2.53 million, a 785% increase year-over-year, driven by its five acquisitions. The company's balance sheet now includes $100.4 million held in trust by its sponsored SPAC, NorthStrive Acquisition Corp I, which has a proposed business combination with Nuclea Energy. Despite a net loss, gross profit rose, and operating expenses decreased quarter-over-quarter.
Five things for pharma marketers to know for Monday, November 16, 2026
This article outlines five key developments for pharma marketers, including conflict-of-interest questions surrounding Oura's acquisition of a telehealth provider tied to Eli Lilly, Boston Scientific's extensive marketing of its Watchman device, and new American Cancer Society guidelines for prostate cancer screening. It also covers federal funding for ibogaine PTSD studies despite safety concerns and a ProPublica story on a faith-healing sect in Idaho.
Endobronchial Tubes Market Size, Share & Forecast 2036
The Endobronchial Tubes Market is projected to grow from USD 416.2 million in 2026 to USD 739.1 million by 2036, at a CAGR of 5.9%. This growth is driven by the increasing demand for advanced airway management in complex thoracic procedures and the adoption of visualization-enabled lung isolation devices. Double-lumen tubes are expected to maintain their lead in product demand, particularly with integrated video capabilities.
Edwards Lifesciences Corporation (EW) stock price, news, quote and history
Edwards Lifesciences Corporation (EW) stock is currently trading at $107.15, up 1.28%, with an after-hours price of $106.50. The company, a medical device provider specializing in cardiovascular diseases, has seen a YTD return of 25.69% and a 1-year return of 24.43%. Analysts have an average price target of $113.39, with TD Cowen recently raising its price target to $121 and maintaining a Buy rating.
Blackstone is becoming a biotech bank
Blackstone Life Sciences is increasingly acting as a biotech bank, financing drug development for major pharmaceutical companies like Pfizer. This strategy reverses the traditional private-to-public market flow in biotech, with Blackstone investing up to $1.5 billion in Pfizer's GLP-1 receptor agonist, berobenatide. The firm stands to gain from regulatory approvals and commercial sales milestones.
Coherent and Boston Scientific have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research has named Coherent (COHR) as the Bull of the Day due to its strong September quarter results, 50% revenue growth, and raised long-term gross margin target, driven by a significant $20 billion LTA deal. Conversely, Boston Scientific (BSX) is designated as the Bear of the Day, with lowered EPS estimates and flatlining growth forecasts following its Q2 and Q3 results. The article also provides an analysis of CoreWeave, Inc. (CRWV), highlighting its record Q3 revenue and substantial backlog, while cautioning about rising interest expenses and high debt.
Coherent and Boston Scientific have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research has named Coherent as the Bull of the Day due to its strong September quarter, impressive revenue growth, and raised long-term gross margin target, driven by significant demand for its optical components. Conversely, Boston Scientific has been designated the Bear of the Day, as analysts have lowered its EPS estimates for the current and next year due to flatlining growth expectations. Additionally, the article discusses CoreWeave's record Q3 revenue and substantial backlog, alongside concerns about its rising interest expense and high debt.
Heartflow Beats Big And Raises Again As Plaque Ramps, But A 51% Run Leaves Little Room For The Implied Q4 Slowdown
Heartflow Inc. reported a strong Q3 with accelerating revenue, a fourth consecutive full-year guidance raise, and shrinking losses, driven by a 57.4% year-over-year revenue increase and significant Plaque Analysis growth. However, the stock's recent 51% rally has already priced in much of the good news, and Q4 guidance implies a slowdown due to factors like flat Plaque pricing and holiday seasonality. Despite the improved fundamentals and rich catalyst slate, the challenge remains whether the stock's current valuation leaves room for further upside given the anticipated Q4 deceleration.
Boston Scientific Corp. stock underperforms Thursday when compared to competitors
Shares of Boston Scientific Corp. (BSX) fell by 2.06% to $44.20 on Thursday, breaking a three-day winning streak. This underperformance occurred during a generally poor trading session for the stock market, with both the S&P 500 Index and Dow Jones Industrial Average also declining.
Carlisle Companies (NYSE:CSL) Coverage Initiated by Analysts at Northcoast Research
Northcoast Research has initiated coverage on Carlisle Companies (NYSE:CSL) with a "buy" rating and a price target of $470.00, suggesting an 18.25% upside. The company recently surpassed quarterly earnings estimates, reporting EPS of $5.92 and revenue of $1.46 billion, an 8.6% increase year-over-year. Currently, analyst sentiment is moderately positive, with an average target price of $406.43 from five "buy" and five "hold" ratings.
Teleflex stock hits 52-week high at 156.75 USD
Teleflex Inc (NYSE:TFX) has reached a new 52-week high of $156.75, reflecting a 29% year-to-date return and a 42.85% increase over the past year. InvestingPro analysis indicates the stock is still undervalued with a Fair Value of $186.80. This performance follows stronger-than-expected Q3 2026 results and analyst price target increases.
Former Medtronic and Baxter International Executives Join Chapman & Co. Leadership Institute, Expanding Healthcare and MedTech Expertise
Chapman & Co. Leadership Institute has announced the addition of Jeanne Mason, former executive vice president and chief human resources officer of Baxter International, and Carla Skinner, former senior director of Medtronic's Global Sales Excellence, to its senior leadership team. This expansion aims to bolster the firm's expertise in healthcare, life sciences, and MedTech organizations, bringing decades of experience in leadership development, culture transformation, and organizational change. Their appointments are set to enhance the consultancy's ability to help clients align strong culture with robust business results in complex and highly regulated industries.
Did Profitable Quarter Just Shift AtriCure (ATRC) Stock Investment Narrative?
AtriCure (ATRC) reported a profitable third quarter in 2026, with revenue of US$154.45 million and net income of US$4.06 million, marking a significant shift from previous losses. The company also provided full-year 2026 guidance, indicating sustained profitability. This development suggests that AtriCure's cost structure and product mix are now effectively supporting earnings alongside growing sales, potentially altering the investment narrative for the medical equipment company.
Alcon shares fall as US implant lens competition and a $58 million tariff refund cloud its third quarter
Alcon's shares fell after its Q3 results revealed a decline in implantable lens sales due to US competition and operating profit boosted by a one-off $58 million tariff refund. While overall sales rose 5% to $2.72 billion, intraocular lens sales dropped, causing analysts to note that without the refund, operating profit would have missed expectations. The company narrowed its 2026 sales and core EPS guidance amidst uncertainty about its growth trajectory.
Insider Buying Signals: 3 Healthcare Stocks to Watch
Jonathan Rose highlights three healthcare stocks—Prothena Corporation (PRTA), Rapport Therapeutics, Inc. (RAPP), and Azenta, Inc. (AZTA)—that have caught his attention due to insider purchases or corporate buybacks. While these actions signal confidence, Rose emphasizes that they are merely starting points for research, not immediate buy recommendations, and stresses the importance of further investigation into financial strength and catalysts. He details why each stock is on his watchlist, noting their balance sheets, upcoming clinical data, and growth outlooks, while also cautioning about the inherent risks in the biotechnology sector and market conditions.
Wondering Why Omnicell Fell? Here's What Bears Saw
Omnicell's stock (NasdaqGS:OMCL) has fallen 20.5% year-to-date in 2026, driven by mixed Q3 results that showed revenue decline but improved net income. While bullish arguments focused on SaaS growth and higher profit margins, bearish concerns about government cost controls and cybersecurity spending appear to have been partially validated. Future performance hinges on the success of its Titan XT and OmniSphere refreshes in converting pipeline into durable, higher-margin recurring revenue.
Spectral AI - Class A Share News - Latest Updates, Live News & More
Spectral AI's latest news indicates a challenging Q3 FY26 with sales missing estimates, despite EPS beating consensus. The company's revenue declined by 24.7% year-over-year, leading to a lowered full-year revenue guidance. However, Spectral AI secured significant non-dilutive funding and continues to showcase its DeepView System, which recently received FDA De Novo Classification and UKCA authorization, with commercial sales expected by the end of 2026.
Sales rose to $1.14M, but Elutia (ELUT) posted a wider Q3 loss from continuing operations.
Elutia Inc. (ELUT) reported increased net sales of $1.137 million in Q3 2026, up from $944,000 a year earlier, but its net loss from continuing operations widened significantly to $6.503 million, from $1.044 million. The company's R&D expenses notably increased by 173.6% as it aggressively develops its next-generation biologic matrices, NXT-41 and NXT-41x. Elutia is also working to regain compliance with Nasdaq's minimum bid price requirement by February 2, 2027, following its stock trading below $1.00 for 30 consecutive business days.
Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
Stereotaxis (NYSE: STXS) reported a 20% increase in third-quarter 2026 revenue to $8.9 million, driven by strong system sales and growth in robotically-navigated catheters. The company is focusing on transitioning to more accessible and scalable systems and developing disposable interventional catheters for recurring revenue. Stereotaxis also announced a convertible note financing of up to $24 million to bolster its cash balance and support future growth.
Autonomix Medical receives new U.S. patent for catheter sensing technology
Autonomix Medical announced the issuance of a new U.S. Patent for "Medical Devices With Circuitry For Capturing And Processing Physiological Signals." This patent strengthens the intellectual property for their catheter sensing technology, which is designed for high-resolution sensing and real-time physiological monitoring near the biological source. The company believes this technology could have applications in various medical procedures, though it is currently investigational and not cleared for marketing.
Boston Scientific Corp. stock outperforms competitors on strong trading day
Shares of Boston Scientific Corp. (BSX) rose 1.54% to $44.70 on Tuesday, outperforming the broader market which saw the S&P 500 Index (SPX) fall 0.38% and the Dow Jones Industrial Average (DJIA) fall 0.30%. This marked the second consecutive day of gains for the stock.
Medtronic PLC stock underperforms Tuesday when compared to competitors
Medtronic PLC (MDT) shares fell by 1.17% on Tuesday, closing at $101.59, as the broader stock market also experienced a downturn. The company's stock underperformed both the S&P 500 and the Dow Jones Industrial Average, which also saw declines. Medtronic PLC finished the trading session 4.46% below its 52-week high.
Enovis (NYSE:ENOV) Q3 2026: Recon Growth, Guidance Raised
Enovis (NYSE:ENOV) reported strong Q3 2026 results, with sales growth on both reported and organic bases, driven by significant market share gains in its Reconstructive segment. The company also raised its full-year guidance for adjusted EBITDA and adjusted EPS, reflecting confidence in margin improvement and successful execution of its innovation-led strategy. This performance highlights Enovis's ability to capitalize on steady demand from an aging population and advancements in orthopedic medical technology.
Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device
Eocene Ltd. has signed its first European commercial distribution agreement for its CG-100 device with Hospital Line SA, granting Hospital Line exclusive rights to market, sell, and distribute CG-100 in Greece and Cyprus. This agreement marks an important step in Colospan's European commercialization strategy, with plans for a launch at the 17th Hellenic-Cypriot Surgical Conference, aiming to reduce the need for diverting stomas in colorectal surgery. The CG-100 device, which has FDA Breakthrough Device Designation and CE Mark, is intended to protect colorectal anastomoses.
Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced the sale of its 1,000th superficial radiotherapy (SRT) system, a major commercial milestone. This achievement underscores the company's commitment to providing non-invasive treatment options for non-melanoma skin cancer and reflects increased physician awareness and dedicated reimbursement codes for SRT. Sensus Healthcare plans to continue expanding access to this technology, aiming for the next 1,000 units.
Eocene's Colospan unit signs first European deal for CG-100 device
Eocene Ltd.'s subsidiary, Colospan Ltd., has secured its first European distribution agreement with Hospital Line SA for its CG-100 intraluminal bypass device in Greece and Cyprus. This agreement marks a significant milestone for Colospan's European expansion, with a commercial launch planned to coincide with the ongoing U.S. pivotal study of CG-100. The device holds a CE mark and FDA Breakthrough Device Designation and aims to offer an alternative to diverting stomas in colorectal surgery.
Adagio Medical treats 22 patients in vCLAS Ultra catheter sub-study
Adagio Medical Holdings, Inc. has treated 22 patients with its vCLAS Ultra Ultra-Low Temperature Ablation ventricular ablation system across seven centers in the United States and Canada. This includes 19 patients in the FULCRUM-VT IDE sub-study and three compassionate use cases. Physicians are reporting reduced ablation times and improved performance compared to the first-generation system.
Orthofix Q3 Revenue Misses Estimates by $2.62 Million as EPS Beats
Orthofix Medical Inc. reported third-quarter revenue of $207.9 million, missing analyst estimates by $2.62 million, despite a 1.1% year-over-year increase. The company's GAAP loss per share of $0.15 was 12 cents better than expected. Cash and cash equivalents decreased sequentially to $86.9 million from $104.4 million due to working-capital timing.
RadNet Q3 2026 Earnings Call Transcript
RadNet, Inc. reported record third-quarter revenue of $683 million, a 22.1% increase year-over-year, and adjusted EBITDA of $105 million, a 23.8% increase, driven by demand in advanced imaging, new centers, and joint ventures. The company announced the acquisition of ONRAD, forming a new Radiology Professional Services segment, expected to add significant revenue and EBITDA. RadNet also raised its 2026 full-year guidance for Imaging Center revenue, adjusted EBITDA, and free cash flow due to strong performance and digital health growth.
Stryker stock faces lower 2026 outlook after Q3 earnings miss
Stryker Corp. has lowered its full-year 2026 outlook following a third-quarter performance that fell short of management expectations, despite reporting stronger sales growth. While adjusted operating margin expanded, a goodwill impairment impacted reported earnings. The company now forecasts reduced organic sales growth and adjusted diluted earnings per share, raising execution pressure for investors.
Novocure denied FDA approval for metastatic cancer treatment
Novocure has been denied FDA approval for its Optune Mya device, intended to treat non-small cell lung cancer that has spread to the brain. The FDA cited uncertainty regarding the degree of clinical benefit, despite not raising safety concerns. Novocure plans to meet with the FDA to explore options for approval without additional clinical studies.
Former Boston Scientific Executive Joins Vascular Technology Board
Vascular Technology Incorporated (VTI) has appointed David Pierce, a former executive vice president at Boston Scientific Corp., to its Board of Directors. Pierce brings over 30 years of experience in the medical device and healthcare technology markets, and his expertise is expected to help VTI expand and strengthen customer relationships. This appointment aims to support VTI's growth in surgical devices, particularly in endoscopic therapies.
What STERIS (STE) Said on Its Q2 Earnings Call
STERIS (STE) raised its fiscal 2027 earnings outlook after reporting strong second-quarter revenue and profit, driven by tariff refunds and robust Life Sciences equipment shipments. The company now expects diluted EPS of $11.35 to $11.55 and maintained its full-year revenue growth forecast. STERIS also announced a planned acquisition of Xodus Medical to expand its consumables offering and a restructuring plan to achieve annualized savings.